ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
Ossia M. Eichhoff(University of Zurich), Mitchell P. Levesque(University of Zurich), Andrea Aloia(ETH Zurich), Nina Zila(Medical University of Vienna), Annalisa Saltari(University Hospital of Zurich), Susana Pascoal(St Anna Children's Hospital), Vasanthi S. Viswanathan(Broad Institute), Andreas Dzung(University Hospital of Zurich), Martin Distel(St Anna Children's Hospital), Zsolt Balázs(Quantitative BioSciences), Michael Krauthammer(Quantitative BioSciences), Alaa Othman(University of Zurich), Corinne I. Stoffel(University of Zurich), Stuart L. Schreiber(Broad Institute), Thorsten Hornemann(University of Zurich), Gergely Karsai(University of Zurich), Jan Käsler(University Hospital of Zurich), Berend Snijder(SIB Swiss Institute of Bioinformatics), Phil F. Cheng(University Hospital of Zurich), Judith Wenzina(Medical University of Vienna), Patrick Turko(University Hospital of Zurich), Pål Johansen(University Hospital of Zurich), Anja Irmisch(University of Zurich), Julien Mena(ETH Zurich), Luzia Briker(University Hospital of Zurich), Aizhan Tastanova(University Hospital of Zurich), Reinhard Dummer(University of Zurich), Nicola Zamboni(ETH Zurich), Andrea Bileck(University of Vienna), Rebekka Wegmann(ETH Zurich), Verena Paulitschke(University Hospital of Zurich), Alexander Leitner(ETH Zurich)
Cited by 24
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k